Ptc Therapeutics (PTCT) Acquisitions (2017 - 2018)
Ptc Therapeutics (PTCT) posted quarterly Acquisitions of $48.9 million for Q3 2018, up 163.97% year-over-year from $18.5 million in Q3 2017, and up 163.97% quarter-over-quarter from -$76.4 million in Q3 2017.
Powered by 
Analysis
Ptc Therapeutics (PTCT) Acquisitions (2017 - 2018) Analysis & Trends
Ptc Therapeutics' Acquisitions history runs 2 years deep, the most recent figure standing at $48.9 million for Q3 2018.
- In Q3 2018, Acquisitions rose 163.97% year-over-year to $48.9 million; the TTM figure through Dec 2019 stood at $48.9 million (up 277.58% YoY), while the FY2018 annual figure was $48.9 million, changed N/A from the prior year.
- Acquisitions for Q3 2018 stood at $48.9 million, up from -$76.4 million in the prior quarter.
- The five-year high for Acquisitions was $48.9 million in Q3 2018, with the low at -$76.4 million in Q3 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Ptc Therapeutics | 5.78 Bn | 3.55 Bn | 340.60 Mn | - |